RxDoctor Payments Data

Roanna Alcera, MD

Family Medicine · Hainesport, NJNPI 1992960991

Payments from drug & device makers

$1,182in general payments, 2019–2025

Across 54 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$629
  • AstraZeneca$223
  • Teva Pharmaceuticals USA, Inc.$133
  • Abbott$93
  • Novo Nordisk$38
  • Idorsia Pharmaceuticals US Inc$30
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$1,182100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)34$629
AstraZeneca9$223
Teva Pharmaceuticals USA, Inc.2$133
Abbott1$93
Novo Nordisk3$38
Idorsia Pharmaceuticals US Inc2$30
Lilly USA, LLC2$26
Althera Pharmaceuticals LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,182 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$31,837
Medicare patients
112
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate39$49,175
EliquisApixaban28$34,825
JardianceEmpagliflozin24$28,354
OzempicSemaglutide17$24,496
Janumet XrSitagliptin Phos/Metformin Hcl18$20,534
TrulicityDulaglutide20$19,344
AbrysvoRsv Vacc, Pref A And Pref B/Pf18$5,296
ShingrixVaricella-Zoster Ge/As01b/Pf13$2,826
Atorvastatin Calcium240$2,674
Montelukast Sodium109$1,690
Rosuvastatin Calcium97$1,605
Levothyroxine Sodium123$1,512
Gabapentin101$1,419
Albuterol Sulfate HfaAlbuterol Sulfate47$1,217
Losartan Potassium110$1,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$38$24,49617 claims
Lilly USA, LLCTrulicity$26$19,34420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Hainesport

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →